Repligen's company performance was boosted by strong biopharma demand and revenue from consumables and capital equipment.
1 report, 1 independent
Updated Jul 29
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Repligen's company performance was boosted by strong biopharma demand and revenue from consumables and capital equipment.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Repligen
bioTech Company
Nothing else this week.
Coverage
Newest first; wire copies grouped- StockStoryRepligen’s (NASDAQ:RGEN) Q2 Sales Top Estimates, Full-Year Sales Guidance is Optimistic Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q2 CY2025 results beating Wall Stre